Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07872025
ABSTRACT:
Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
REFERENCES:
patent: 3682930 (1972-08-01), Bourquin et al.
patent: 3862156 (1975-01-01), Bourquin et al.
patent: 3994974 (1976-11-01), Murakami et al.
patent: 4073915 (1978-02-01), Martin
patent: 4128549 (1978-12-01), Bourquin et al.
patent: 5168098 (1992-12-01), Esanu et al.
patent: 5674860 (1997-10-01), Carling et al.
patent: 6040344 (2000-03-01), Gao et al.
patent: 6207684 (2001-03-01), Aberg
patent: 6306369 (2001-10-01), Akehurst et al.
patent: 7226934 (2007-06-01), Aberg et al.
patent: 263 993 (1988-09-01), None
patent: 0 339 978 (1989-11-01), None
patent: 1.441.486 (1966-11-01), None
patent: 1.447.527 (1966-11-01), None
patent: 98/43640 (1988-10-01), None
patent: 98/56381 (1988-12-01), None
Kelly “Non-cortecosteroid therapy for . . . ” Exp. opinionPharmacother. 8(13) p. 2077-2087 (2007).
The Merk Manual. Eleven Edition p. 1266.
Polivka et al. “4H-benzo . . . ” CA 112:216595 (1990).
Cundy et al. “Evidence of stereospecificity in the invivo . . . ” Embase 1985022681 (1985).
Bourgeois et al. “Pharmacokinetics of R-enantimeric . . . ” Embase 1986195020 (1986).
Boos et al. “Urinary excretion of the enantiomers . . . ” Embase 19913160244 (1991).
Garattini “Active drug metabolites . . . ” Clin. Pharmacokinetics vol. 10, p. 216-227 (1985).
Jamali et al. “Bi-directional chiral inversion . . . ” Chirality v. 9, p. 29-31 (1997).
Chen et al. “Determination of Ketotifen . . . ” Rapid Commun. Mass spectrum v. 17, p. 2459-2463 (2003).
Waldvogel et al.; “untersuchungen uber synthetishce Arzneimittle.” Helv. Chim. Acta, 1976, 59; 866-877.
Kennedy, G.R.: “Metabolism and pharmacokinetics of Ketotifen in children” Research and Clinical forums, 1982, 4: 17-29.
Julien-Larose C et al.; “Quantification of Ketotifen and its metabolites in human plasma by gas chromatography mass spectrometry” Biomed Mass Spectrom. 1983, 10: 136-139.
Le Bigot et al.: “Metabolism of Ketotifen by human liver microsomes. In vitro characterization of a tertiary amine glucuronidation” Drug Metab. Dispos. 1983, 11: 585-589.
Le Bigot et al.: “Species differences in metabolism of Ketotifen in rat, rabbit and man” Life Sci., 1987, 40: 883-890.
Polivka Z. et al.: “4H-benzo(4,5) cyclohepta(1,2-b)thiophenes and 9,10-dihydro derivatives-sulfonium analogues of pizotifen and Ketotifen; chirality of Ketotifen; synthesis of the 2-bromo derivative of Ketotifen.” Collect. Czech. Chem. Commun. 1989, 54: 2443-2469.
Mey, U. et al.; “Conjugation of the enantiomers of Oetotifen to four isomeric quaternary ammonium glucuronides in humans in vivo and in liver microsomes.” Drug Metab Dispos 1999, 27: 1281-1292.
Mey, U et al.; “Enantioselective N-glucuronidation of Ketotifen in humans in vitro and in vivo”; Naunyn-Schmiedeberg's Arch Pharmacol 1999, 359: 135 (Abstract).
Breyer-Pfaff, U. et al.: “Stereoselective high-affinity reduction of ketonic nortriptyline metabolites and of Ketotifen by aldo-keto reductases from human liver”; Adv. Exp Med Biol. 1999, 463: 473-480.
Breyer-Pfaff, U. et al.: High-affinity stereoselective reduction of the enantiomers of Ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver Biochem Pharmacol 2000, 59: 249-260.
Database CAS on STN, (Columbus, OH, USA) AN 113:40470 CA, Polivka el al. “process for preparing pure enantiomers of 4-(1-methyl-4-piperidylidene-4, 9- dihydrobenzo[4,5]cyclohepta[1,2-b]thiophen-10-one as antihistaminics and antianaphylactics”., 1989.
Database CAS on STN, (Columbus, OH, USA) AN 112:216595 CA. Polivka et al. “4H-benzo[4,5-cyclohepta]1,2-bthiophenes and 9, 10-dihydro derivatives. Sulfonium analogs of pizotifen and ketoeifen. Chirality of Ketotifen. Synthesis of the 2-bromo derivative of ketorifen”. Coll. Czech, Chem. Commun. 91989) vol. 54(9), pp. 2443-2469.
Kofler et al. Experimental chemistry—organic chemistry and reaction. Japan Chemical Society. 1957, vol. 1, pp. 504-505 (Japanese).
Database Caplus on STN. (Columbus, OH, USA) AN 1999:793640 Breyer-Pfaff et al. “High-affinity stereoselective reduction of the enantiomers of Ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases” Biochem. Pharmacol. 1999 vol. 59(3), pp. 240-260.
Helvetica Chimica Acta-vol. 59, (1976) pp. 866-877; Erwin Waldvogel et al. “Untersuchungen uber syntehtische Arzneimittel 9-und 10-Oxo-derivate von 9, 10-dihydro-4H-benzol[4,5]cyclohepta[1,2-b]thiophenen”.
Chirality v. 9, p. 29-31 (1997); Fakhreddin Jamali et al.; “Bi-Directional Chiral Inversion of Ketoprofen in CD-1 Mice”.
Rapid Commun. Mass spectrum v.17, p. 2459-2463 (2003); Xiaoyan Chen et al.; “Determination of Ketotifen and its conjugated metabolite in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study”.
Electrophoresis 23: 456-461 (2002); M. Brent Busby et al. “Nonaqueous capillary electrophoretic separation of basic enantiomers using octakis(2,3-0-dimethyl-6-O-sulfo)-γ-cyclodextrin, a new, single-isomer chiral resolving agent”.
European communication dated Sep. 7, 2009.
Brazilian communication dated Nov. 24, 2009.
European communication dated Apr. 14, 2010 in a corresponding foreign application (00966709.8).
Drugs: Drug Evaluation: PDF only; “Formoterol: A Review of its Pharmacological Properties and Therapeutic Potential in Reversible Obstructive Airways Disease”; Faulds, Diana et al.; 2-pages.; http://adisonline.com/drugs/Abstract/1991/42010/Formoterol—A—Review—of—its—Pharmacological.7.aspx.
PDR Generics, 1995, First Edition, Medical Economics, Montvale, New Jersey, pp. 53-59; Albuterol.
Examiner's Opinion published Jun. 29, 2010 in Brazil in co-pending foreign application (PI0013935-1).
European communication dated Aug. 12, 2010 in a corresponding foreign application (EP00966709.8).
Argentine communication dated Sep. 13, 2010 in corresponding foreign application (AR034396).
Aberg A. K. Gunnar
Chen Jan L.
Maioli Andrew T.
Wright George E.
Bridge Pharma, Inc.
Chang Celia
Nields, Lemack & Frame, LLC
LandOfFree
Optically active isomers of ketotifen and therapeutically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optically active isomers of ketotifen and therapeutically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optically active isomers of ketotifen and therapeutically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686748